OBJECTIVES: To study the tolerance and acceptability in Africa of a perinatal intervention to prevent vertical HIV transmission using benzalkonium chloride disinfection. DESIGN: A randomized, double blinded phase II trial. SETTING:Prenatal care units in Abidjan (Côte d'Ivoire) and Bobo-Dioulasso (Burkina Faso). PATIENTS: Women accepting testing and counselling who were seropositive for HIV-1 and under 37 weeks of pregnancy were eligible. A total of 108 women (54 in each group) enrolled from November 1996 to April 1997, with their informed consent. INTERVENTION: Women self administered daily a vaginal suppository of 1% benzalkonium chloride or matched placebo from 36 weeks of pregnancy, and a single intrapartum dose. The neonate was bathed with 1% benzalkonium chloride solution or placebo within 30 minutes after birth. MAIN OUTCOME MEASURES: Adverse events were recorded weekly, with a questionnaire and speculum examination in women through delivery, and examination of the neonate through day 30. The incidence of genital signs and symptoms in the women and cutaneous or ophthalmological events in newborns were compared between groups on an intent to treat basis. RESULTS: The median duration of prepartum treatment was 21 days (range 0-87 days). Compliance was 87% for prepartum and 69% for intrapartum treatment, and 88% for the neonatal bath, without differences between the two groups. In women, the most frequent event was leucorrhoea; the incidence of adverse events did not differ between treatment groups. In children, the incidence of dermatitis and conjunctivitis did not differ between the benzalkonium chloride and placebo groups (p = 0.16 and p = 0.29, respectively). CONCLUSION:Vaginal disinfection with benzalkonium chloride is a feasible and well tolerated intervention in west Africa. Its efficacy in preventing vertical HIV transmission remains to be demonstrated.
RCT Entities:
OBJECTIVES: To study the tolerance and acceptability in Africa of a perinatal intervention to prevent vertical HIV transmission using benzalkonium chloride disinfection. DESIGN: A randomized, double blinded phase II trial. SETTING: Prenatal care units in Abidjan (Côte d'Ivoire) and Bobo-Dioulasso (Burkina Faso). PATIENTS: Women accepting testing and counselling who were seropositive for HIV-1 and under 37 weeks of pregnancy were eligible. A total of 108 women (54 in each group) enrolled from November 1996 to April 1997, with their informed consent. INTERVENTION: Women self administered daily a vaginal suppository of 1% benzalkonium chloride or matched placebo from 36 weeks of pregnancy, and a single intrapartum dose. The neonate was bathed with 1% benzalkonium chloride solution or placebo within 30 minutes after birth. MAIN OUTCOME MEASURES: Adverse events were recorded weekly, with a questionnaire and speculum examination in women through delivery, and examination of the neonate through day 30. The incidence of genital signs and symptoms in the women and cutaneous or ophthalmological events in newborns were compared between groups on an intent to treat basis. RESULTS: The median duration of prepartum treatment was 21 days (range 0-87 days). Compliance was 87% for prepartum and 69% for intrapartum treatment, and 88% for the neonatal bath, without differences between the two groups. In women, the most frequent event was leucorrhoea; the incidence of adverse events did not differ between treatment groups. In children, the incidence of dermatitis and conjunctivitis did not differ between the benzalkonium chloride and placebo groups (p = 0.16 and p = 0.29, respectively). CONCLUSION: Vaginal disinfection with benzalkonium chloride is a feasible and well tolerated intervention in west Africa. Its efficacy in preventing vertical HIV transmission remains to be demonstrated.
Authors: R J Biggar; P G Miotti; T E Taha; L Mtimavalye; R Broadhead; A Justesen; F Yellin; G Liomba; W Miley; D Waters; J D Chiphangwi; J J Goedert Journal: Lancet Date: 1996-06-15 Impact factor: 79.321
Authors: L G Burman; P Christensen; K Christensen; B Fryklund; A M Helgesson; N W Svenningsen; K Tullus Journal: Lancet Date: 1992-07-11 Impact factor: 79.321
Authors: J Kreiss; E Ngugi; K Holmes; J Ndinya-Achola; P Waiyaki; P L Roberts; I Ruminjo; R Sajabi; J Kimata; T R Fleming Journal: JAMA Date: 1992 Jul 22-29 Impact factor: 56.272
Authors: L Mandelbrot; P Msellati; N Meda; V Leroy; R Likikouët; P Van de Perre; L Dequae-Merchadoux; F Sylla-Koko; A Ouangre; T Ouassa; R Ramon; L Gautier-Charpentier; M Cartoux; M Dosso; F Dabis; C Welffens-Ekra Journal: Sex Transm Infect Date: 2002-08 Impact factor: 3.519
Authors: Renaud Becquet; Milly Marston; François Dabis; Lawrence H Moulton; Glenda Gray; Hoosen M Coovadia; Max Essex; Didier K Ekouevi; Debra Jackson; Anna Coutsoudis; Charles Kilewo; Valériane Leroy; Stefan Z Wiktor; Ruth Nduati; Philippe Msellati; Basia Zaba; Peter D Ghys; Marie-Louise Newell Journal: PLoS One Date: 2012-02-23 Impact factor: 3.240
Authors: Shino Arikawa; Nigel Rollins; Gonzague Jourdain; Jean Humphrey; Athena P Kourtis; Irving Hoffman; Max Essex; Tim Farley; Hoosen M Coovadia; Glenda Gray; Louise Kuhn; Roger Shapiro; Valériane Leroy; Robert C Bollinger; Carolyne Onyango-Makumbi; Shahin Lockman; Carina Marquez; Tanya Doherty; François Dabis; Laurent Mandelbrot; Sophie Le Coeur; Matthieu Rolland; Pierre Joly; Marie-Louise Newell; Renaud Becquet Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Emanuele Sozzi; Mahnoor Baloch; Joseph Strasser; Michael B Fisher; Mats Leifels; Juan Camacho; Nadia Mishal; Sam F Elmes; Grace Allen; Gregory Gadai; Lexi Valenti; Mark D Sobsey Journal: Int J Hyg Environ Health Date: 2018-11-10 Impact factor: 5.840